文献速递关节外科骨肿瘤创伤骨科

银涂层对初次与翻修关节置换术模块化假体周围关节感染风险的影响:系统综述与Meta分析

Impact of Silver Coating on Periprosthetic Joint Infection Risk in Modular Endoprostheses Used in Primary and Revision Arthroplasty: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Arthroplasty · 2025-09-11

该系统综述与Meta分析纳入13项研究共1517例患者(银涂层707例、无涂层810例),比较银涂层与无涂层钛假体在肿瘤初次重建和翻修关节置换中的假体周围关节感染风险。银涂层假体在初次肿瘤重建后PJI风险降低14%(RR 0.86,95%CI 0.59-1.24,P=0.41),翻修后再感染风险降低19%(RR 0.81,95%CI 0.48-1.12,P=0.21),但所有结局置信区间均涵盖有意义的获益与潜在危害,证据精确性不足支持常规使用。

要点

  • 初次肿瘤重建后银涂层假体PJI风险降低14%(RR 0.86,95%CI 0.59-1.24,P=0.41),未达统计学显著。
  • 翻修关节置换后银涂层假体再感染风险降低19%(RR 0.81,95%CI 0.48-1.12,P=0.21)。
  • 银涂层假体感染患者接受DAIR+手术的可能性更高(RR 4.08,95%CI 1.14-14.55,P=0.03)。

核心结论

  • 银涂层假体在感染率和截肢率方面表现出一致性降低,但置信区间涵盖有意义的获益与潜在危害。
  • 当前证据缺乏足够精确性以支持常规使用,需要足够把握度的试验来确立明确推荐。

研究设计与样本

  • 系统综述与Meta分析,已在国际前瞻性系统综述注册平台注册(CRD420250651012)。
  • 检索PubMed和Embase数据库从建库至2025年2月,纳入比较银涂层与无涂层钛假体的研究。
  • 共纳入13项研究,1517例患者(银涂层707例,无涂层810例)。

主要发现

  • 初次肿瘤重建后银涂层假体PJI风险降低14%(RR 0.86,95%CI 0.59-1.24,P=0.41)。
  • 股骨近端置换RR 0.67(P=0.29),胫骨近端置换RR 0.80(P=0.46)。
  • 急性PJI的RR 0.71(P=0.59),慢性PJI的RR 0.95(P=0.85)。
  • 银涂层假体感染患者接受DAIR+手术的可能性更高(RR 4.08,95%CI 1.14-14.55,P=0.03)。
  • 截肢风险降低40%(RR 0.60,95%CI 0.28-1.19,P=0.20);翻修后再感染风险降低19%(RR 0.81,95%CI 0.48-1.12,P=0.21)。

关键数值与推荐

  • 初次肿瘤重建后PJI风险RR 0.86(95%CI 0.59-1.24,P=0.41)。
  • 翻修关节置换后再感染风险RR 0.81(95%CI 0.48-1.12,P=0.21)。
  • DAIR+手术RR 4.08(95%CI 1.14-14.55,P=0.03)。
  • 截肢风险RR 0.60(95%CI 0.28-1.19,P=0.20)。

临床怎么用

  • 当前证据缺乏足够精确性以支持银涂层假体的常规使用。
  • 需要足够把握度的试验来确立明确推荐。

局限性

  • 所有结局的置信区间均涵盖有意义的获益与潜在危害。
  • 当前证据缺乏足够精确性以支持常规使用。
  • 需要足够把握度的试验来确立明确推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Periprosthetic joint infection (PJI) remains a devastating complication in endoprosthetic reconstruction. Silver coatings have emerged as a potential solution because of their inherent antimicrobial properties, yet their comparative effectiveness against traditional titanium implants remains under debate. METHODS: We conducted a systematic review and meta-analysis following with prior International Prospective Register of Systematic Reviews registration (CRD420250651012). The PubMed and Embase databases were searched from inception to February 2025. Studies comparing silver-coated and uncoated titanium endoprostheses were included. Primary outcomes included PJI after primary oncologic reconstruction and PJI reinfection after revision arthroplasty for failed total joint arthroplasty. There were 13 studies comprising 1,517 patients (707 silver-coated, 810 uncoated) included. RESULTS: Silver-coated endoprostheses showed a 14% reduction in PJI risk after primary oncologic reconstruction (risk ratio [RR] 0.86, 95% confidence interval [CI] 0.59 to 1.24, P = 0.41). Similar reductions were observed for proximal femoral (RR 0.67, P = 0.29) and proximal tibial replacements (RR 0.80, P = 0.46). Silver coating showed reductions in both acute (RR 0.71, P = 0.59) and chronic PJI (RR 0.95, P = 0.85). Patients who had silver-coated implants developing PJI were more likely to undergo debridement, antibiotics, and implant retention plus procedures (RR 4.08, 95% CI 1.14 to 14.55, P = 0.03) and showed a 40% reduction in amputation risk (RR 0.60, 95% CI 0.28 to 1.19, P = 0.20). In revision cases, silver coating demonstrated a 19% reduction in reinfection risk (RR 0.81, 95% CI 0.48 to 1.12, P = 0.21). Confidence intervals encompassed both meaningful benefit and potential harm across all outcomes, but the selection of debridement, antibiotics, and implant retention plus treatment. CONCLUSIONS: Silver-coated endoprostheses demonstrated consistent reductions in infection and amputation rates, but CIs encompassed both meaningful benefit and potential harm. Current evidence lacks sufficient precision to support routine use. Adequately powered trials are needed to establish definitive recommendations. LEVEL OF EVIDENCE: II.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Gonzalez MR, Ubong SE, Jutte PC, et al. Impact of Silver Coating on Periprosthetic Joint Infection Risk in Modular Endoprostheses Used in Primary and Revision Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2025. PMID: 40945758. doi:10.1016/j.arth.2025.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。